Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study.
暂无分享,去创建一个
H. Yagi | T. Ishimitsu | R. Nagai | T. Kohro | T. Yamazaki | S. Horinaka | S. Suzuki | A. Yabe
[1] J. Higaki,et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[2] M. Shibuya,et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[3] R. Nagai,et al. Gender differences in patients with coronary artery disease in Japan: the Japanese Coronary Artery Disease Study (the JCAD study). , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[4] T. Hong,et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[5] B. Gersh. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2008 .
[6] A. Hirayama,et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2007, The Lancet.
[7] Hiroshi Takahashi,et al. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. , 2007, Clinical therapeutics.
[8] H. Yagi,et al. Nicorandil but not ISDN Upregulates Endothelial Nitric Oxide Synthase Expression, Preventing Left Ventricular Remodeling and Degradation of Cardiac Function in Dahl Salt-sensitive Hypertensive Rats With Congestive Heart Failure , 2006, Journal of cardiovascular pharmacology.
[9] Current status of the background of patients with coronary artery disease in Japan. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[10] M. Kurabayashi,et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. , 2005, American heart journal.
[11] M. Sekiya,et al. Effects of the Long-Term Administration of Nicorandil on Vascular Endothelial Function and the Progression of Arteriosclerosis , 2005, Journal of cardiovascular pharmacology.
[12] A. Skene,et al. Impact of nicorandil in angina: subgroup analyses , 2004, Heart.
[13] K. Wellington,et al. Nicorandil , 2012, Drugs.
[14] T. Chou,et al. Impairment of myocardial protection in type 2 diabetic patients. , 2003, The Journal of clinical endocrinology and metabolism.
[15] M. Hori,et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. , 2002, Journal of the American College of Cardiology.
[16] W. Hillis,et al. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.
[17] N. Standen,et al. Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide , 2001, Circulation.
[18] T. Kato,et al. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. , 2001, American heart journal.
[19] L. Guo,et al. The effect of K(atp)channel activation on myocardial cationic and energetic status during ischemia and reperfusion: role in cardioprotection. , 2001, Journal of molecular and cellular cardiology.
[20] A. Yim,et al. ATP-sensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery. , 2000, The Annals of thoracic surgery.
[21] N. Standen,et al. The sulfonylurea glimepiride does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide , 2000 .
[22] Yongge Liu,et al. Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. , 2000, Journal of the American College of Cardiology.
[23] F. Ashcroft,et al. Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide , 1999, Diabetologia.
[24] K. Fox,et al. Cardioprotection by opening of the KATPchannel in unstable anginaIs this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil , 1999 .
[25] K. Fox,et al. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. , 1999, European heart journal.
[26] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[27] M. Mączewski,et al. The role of adenosine and ATP-sensitive potassium channels in the protection afforded by ischemic preconditioning against the post-ischemic endothelial dysfunction in guinea-pig hearts. , 1998, Journal of molecular and cellular cardiology.
[28] 大野嘉嗣. Nicorandil reduces myocardial infarct size by opening the K[ATP] channel in rabbits , 1998 .
[29] LloydChambless,et al. Population Versus Clinical View of Case Fatality From Acute Coronary Heart Disease , 1997 .
[30] G. Gross,et al. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. , 1997, The American journal of physiology.
[31] G. Grover. Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. , 1997, Canadian journal of physiology and pharmacology.
[32] D Kromhout,et al. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe , 1997 .
[33] N. Taira,et al. Nicorandil as a hybrid between nitrates and potassium channel activators. , 1989, The American journal of cardiology.
[34] S. Holzmann. Cyclic GMP as Possible Mediator of Coronary Arterial Relaxation by Nicorandil (SG‐75) , 1983, Journal of cardiovascular pharmacology.